Jonathan Finn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan finn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Finn Today - Breaking & Trending Today

Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.13

Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.13 and traded as high as $1.55. Atossa Therapeutics shares last traded at $1.46, with a volume of 1,163,998 shares traded. Wall Street Analysts Forecast Growth […] ....

Jonathan Finn , Connor Clark Lunn Investment Management Ltd , Cetera Advisors , Atossa Therapeutics Company Profile , Atossa Therapeutics Inc , Vanguard Group Inc , Virtu Financial , Cantor Fitzgerald , Securities Exchange Commission , Atossa Therapeutics , Get Free Report , Director Jonathan Finn , Exchange Commission , Lunn Investment Management , Atossa Therapeutics Daily ,

Cantor Fitzgerald Reiterates Overweight Rating for Atossa Therapeutics (NASDAQ:ATOS)

Cantor Fitzgerald reissued their overweight rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research note published on Tuesday morning, Benzinga reports. A number of other brokerages have also weighed in on ATOS. HC Wainwright lifted their price target on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company […] ....

Jonathan Finn , Cantor Fitzgerald , Connor Clark Lunn Investment Management Ltd , Atossa Therapeutics Inc , Atossa Therapeutics Company Profile , Vanguard Group Inc , Atossa Therapeutics , Free Report , Get Free Report , Director Jonathan Finn , Lunn Investment Management , Atossa Therapeutics Daily ,

StockNews.com Upgrades Atossa Therapeutics (NASDAQ:ATOS) to Hold

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. A number of other research analysts have also recently commented on ATOS. HC Wainwright boosted their target price on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the […] ....

Jonathan Finn , Securities Exchange Commission , Vanguard Group Inc , Atossa Therapeutics Inc , Connor Clark Lunn Investment Management Ltd , Cantor Fitzgerald , Atossa Therapeutics Company Profile , Atossa Therapeutics , Free Report , Get Free Report , Director Jonathan Finn , Exchange Commission , Lunn Investment Management , Vanguard Group , Atossa Therapeutics Daily ,

HC Wainwright Raises Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.00

Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its target price upped by HC Wainwright from $4.00 to $6.00 in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings […] ....

Jonathan Finn , Atossa Therapeutics Inc , Securities Exchange Commission , Atossa Therapeutics Company Profile , Connor Clark Lunn Investment Management Ltd , Vanguard Group Inc , Atossa Therapeutics , Free Report , Get Free Report , Director Jonathan Finn , Exchange Commission , Lunn Investment Management , Vanguard Group , Atossa Therapeutics Daily ,

Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) posted its earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02, Zacks reports. Atossa Therapeutics Trading Up 4.5 % NASDAQ:ATOS opened at $1.61 on Thursday. The stock has a 50 day moving average of $1.59 and a […] ....

Jonathan Finn , Securities Exchange Commission , Cantor Fitzgerald , Atossa Therapeutics Company Profile , Atossa Therapeutics Inc , Atossa Therapeutics , Get Free Report , Director Jonathan Finn , Exchange Commission , Atossa Therapeutics Daily ,